Array
(
[Ovarian Cancer] => Array
(
[Austin] => https://www.survivornet.com/austin/
[Baltimore] => https://www.survivornet.com/baltimore/
[Charlotte] => https://www.survivornet.com/charlotte/
[Cleveland] => https://www.survivornet.com/cleveland/
[Columbus] => https://www.survivornet.com/columbus/
[Dallas / Ft. Worth] => https://www.survivornet.com/dallas-ftworth/
[Denver] => https://www.survivornet.com/denver/
[Detroit] => https://www.survivornet.com/detroit/
[Indianapolis] => https://www.survivornet.com/indianapolis-ovarian-cancer/
[Louisville] => https://www.survivornet.com/louisville/
[Memphis] => https://www.survivornet.com/memphis/
[Minneapolis] => https://www.survivornet.com/minneapolis/
[Nashville] => https://www.survivornet.com/nashville/
[Phoenix] => https://www.survivornet.com/phoenix/
[Portland] => https://www.survivornet.com/portland/
[Salt Lake City] => https://www.survivornet.com/salt-lake-city/
[San Antonio] => https://www.survivornet.com/san-antonio/
[San Diego] => https://www.survivornet.com/san-diego/
[San Francisco] => https://www.survivornet.com/san-francisco/
[San Jose] => https://www.survivornet.com/san-jose/
[Seattle] => https://www.survivornet.com/seattle/
) [Multiple Myeloma] => Array
(
[Ann Arbor] => https://www.survivornet.com/ann-arbor-michigan-multiple-myeloma-treatment/
[Miami] => https://www.survivornet.com/miami-florida-multiple-myeloma-treatment/
[Phoenix] => https://www.survivornet.com/phoenix-arizona-multiple-myeloma-treatment/
) [Glioma] => Array
(
[Midwest] => https://www.survivornet.com/midwest/
[Southeast] => https://www.survivornet.com/southeast/
) )
Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma Summary The purpose of this study is to determine the highest tolerated dose, safety and activity of HCD122 in patients with Multiple Myeloma who are relapse d after receiving prior treatment .
View Eligibility Criteria Eligibility Criteria Inclusion Criteria: Clinical Diagnosis of MM requiring treatment Refractory or Relapsed Disease At least one prior treatment regimen Male or Female >18 years of age Exclusion Criteria: Prior Allogeneic bone marrow transplant (prior autologous transplant allowed) Intracranial disease or epidural disease Clinically significant cardiac dysfunction or other significant organ dysfunction
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 7 Locations for this study
Dana Farber Cancer Institute StudyCoordinator:CHCD122A2102 Boston Massachusetts, 02115, United States
St. Vincent's Comprehensive Cancer Center Dept. of St. Vincent's Cancer New York New York, 10011, United States
Oregon Health Sciences University Portland Oregon, 97239, United States
University of Pennsylvania--Abramson Cancer Center StudyCoordinator:CHCD122A2102 Philadelphia Pennsylvania, 19104, United States
Fred Hutchinson Cancer Research Center Dept. of FHCRC Seattle Washington, 98109, United States
Novartis Investigative Site Herston Queensland, 4029, Australia
Novartis Investigative Site Prahran Victoria, 3181, Australia
How clear is this clinincal trial information?
Sign Up Sign up now for access to powerful tools, top experts, and customized information to help you fight cancer.
Personalized content tailored to your profile and disease type Access exclusive patient guides Breaking treatment information and expert perspectives and more... Sign Up Now Already have an account? Sign In
Sign Up Already have an account? Sign In
Sign In Don't have an account? Sign Up
Password reset is unavailable because your account was created using 'Sign Up with Google. To continue, please use the Google sign-in button below. Don't have an account? Sign Up